Search results for "Heparin"

showing 10 items of 191 documents

Cationic Proteins Inhibit l-Arginine Uptake in Rat Alveolar Macrophages and Tracheal Epithelial Cells

1999

Eosinophil-derived cationic proteins play an essential role in the pathogenesis of bronchial asthma. We tested whether cationic proteins interfere with the cationic amino-acid transport in alveolar macrophages (AMPhi) and tracheal epithelial cells, and whether L-arginine-dependent pathways were affected. The effect of cationic polypeptides on cellular uptake of [(3)H]-L-arginine, nitrite accumulation, and the turnover of [(3)H]-L-arginine by nitric oxide (NO) synthase and arginase (formation of [(3)H]-L-citrulline and [(3)H]-L-ornithine, respectively) were studied. Poly-L-arginine reduced [(3)H]-L-arginine uptake in rat AMPhi and tracheal epithelial cells in a concentration-dependent manner…

LipopolysaccharidesMalePulmonary and Respiratory MedicineTime FactorsClinical BiochemistryGene ExpressionArginineNitric OxideNitric oxideRats Sprague-DawleyPathogenesischemistry.chemical_compoundRibonucleasesFibrinolytic AgentsMacrophages AlveolarAnimalsNitriteLungMolecular BiologyNitritesArginaseDose-Response Relationship DrugbiologyATP synthaseHeparinLysineCationic polymerizationEpithelial CellsBlood ProteinsCell BiologyEosinophil Granule ProteinsProtamineRatsTracheaArginaseBiochemistrychemistryMajor basic proteinbiology.proteinCitrullineFemaleAmerican Journal of Respiratory Cell and Molecular Biology
researchProduct

Lipoprotein remnants accumulation in end-stage renal disease: evidence of an active role of heparin administration during hemodialysis

2003

Lipoprotein renal disease hemodialysis heparin administration during
researchProduct

Heparin modulates the cellular uptake of nanomedicines

2021

Liposomal formulations are used to improve the safety and cellular absorption of conventional drugs by limiting their interaction with phagocytes. The uptake behaviour of these nanocarriers is affected by the blood composition, and accordingly the presence of an anticoagulant in the blood could have a critical impact on the efficiency of nanomedicines. For the negatively charged liposomes, such as AmBisome®, no significant change in the uptake could be observed when co-incubated with heparin and primary phagocytes. Yet, we observed that a peak of the uptake extent of cationic liposomes was reached at a clinically relevant concentration of heparin for phagocytes and cancer cells. Hence, we r…

Liposomemedicine.drug_classChemistryHeparinAnticoagulantBiomedical EngineeringAnticoagulantsAbsorption (skin)HeparinPharmacologyNanomedicineCationsCancer cellLiposomesmedicineNanomedicineHumansGeneral Materials ScienceCationic liposomeNanocarriersmedicine.drug
researchProduct

Spin‐Labeled Heparins as Polarizing Agents for Dynamic Nuclear Polarization

2010

A potentially biocompatible class of spin-labeled macromolecules, spin-labeled (SL) heparins, and their use as nuclear magnetic resonance (NMR) signal enhancers are introduced. The signal enhancement is achieved through Overhauser-type dynamic nuclear polarization (DNP). All presented SL-heparins show high 1 H DNP enhancement factors up to E=-110, which validates that effectively more than one hyperfine line can be saturated even for spin-labeled polarizing agents. The parameters for the Overhauser-type DNP are determined and discussed. A striking result is that for spin-labeled heparins, the off-resonant electron paramagnetic resonance (EPR) hyperfine lines contribute a non-negligible part…

Magnetic Resonance SpectroscopyMolecular StructureHeparinChemistryElectron Spin Resonance SpectroscopySite-directed spin labelingNuclear Overhauser effectNuclear magnetic resonance spectroscopyElectronAtomic and Molecular Physics and Opticslaw.inventionNuclear magnetic resonancelawMoleculeSpin LabelsCondensed Matter::Strongly Correlated ElectronsPhysical and Theoretical ChemistryElectron paramagnetic resonanceHyperfine structureMacromoleculeChemPhysChem
researchProduct

Head-to-head comparison of plasma cTnI concentration values measured with three high-sensitivity methods in a large Italian population of healthy vol…

2019

Abstract Background The study aim is to compare cTnI values measured with three high-sensitivity (hs) methods in apparently healthy volunteers and patients admitted to emergency department (ED) with acute coronary syndrome enrolled in a large multicentre study. Methods Heparinized plasma samples were collected from 1511 apparently healthy subjects from 8 Italian clinical institutions (mean age: 51.5 years, SD: 14.1 years, range: 18–65 years, F/M ratio:0.95). All volunteers denied chronic or acute diseases and had normal values of routine laboratory tests. Moreover, 1322 heparinized plasma sample were also collected by 9 Italian clinical institutions from patients admitted to ED with clinica…

Male0301 basic medicineprincipal component analysisvery elderlyClinical BiochemistryheparinizationBiochemistryPatient Admission0302 clinical medicineReference ValuesLimit of Detectionblood analysisTroponin IHealthy volunteers80 and overMyocardial infarctionAcute coronary syndrome; Cardiac troponins; High-sensitivity methods; Myocardial infarction; Reference population values; Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged 80 and over; Blood Chemical Analysis; Female; Humans; Italy; Male; Middle Aged; Myocardium; Patient Admission; Reference Values; Troponin I; Young Adult; Emergency Service Hospital; Healthy Volunteers; Limit of DetectionReference population valuescomparative studyHigh-sensitivity methodsAged 80 and overemergency wardEmergency Servicehospital emergency servicetroponin I acute coronary syndromeSettore BIO/12clinical trialGeneral Medicinecardiac troponin 1 CLIAMiddle AgedHealthy Volunteerspriority journalItaly030220 oncology & carcinogenesisCardiac troponinFemaleAcute coronary syndromeEmergency Service HospitalAdultmedicine.medical_specialtyAcute coronary syndromecardiac muscleAdolescentHead to headheart infarctionArticleYoung AdultHospital03 medical and health sciencesbloodInternal medicinemedicinesexHumanscontrolled studyADVIA Centaurdiagnostic test accuracy studyhumannormal humanproceduresAgedbusiness.industryMyocardiumTroponin IBiochemistry (medical)reference valueEmergency departmentmedicine.diseasemajor clinical studyhospital admissionyoung adult Acute Coronary SyndromeHigh-sensitivity methodMyocardial infarctionmulticenter study030104 developmental biologySettore BIO/12 - Biochimica Clinica E Biologia Molecolare Clinicaageprotein blood levelReference valuesCardiac troponinsbusinessmetabolismBlood Chemical Analysis
researchProduct

Early effects of unfractionated heparin on clinical and radiological signs and D-dimer levels in patients with COVID-19 associated pulmonary embolism…

2021

Male2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Unfractionated heparinLetter to the Editors-in-ChiefCohort StudiesFibrin Fibrinogen Degradation ProductsInternal medicineD-dimerHumansMedicineIn patientHeparinbusiness.industryPulmonary embolismCOVID-19HematologyHeparinmedicine.diseaseCOVID-19 Drug TreatmentPulmonary embolismRadiological weaponD-dimerbusinessCohort studymedicine.drug
researchProduct

Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated hep…

2003

Item does not contain fulltext OBJECTIVES: The aim of this study was to evaluate percutaneous coronary intervention (PCI) in the Assessment of the Safety and Efficacy of New Thrombolytic Regimens (ASSENT-3) trial. BACKGROUND: In the ASSENT-3 trial, co-therapy with abciximab (ABC) or enoxaparin (ENOX) reduced ischemic complications after ST-elevation acute myocardial infarction treated with tenecteplase when compared with unfractionated heparin (UFH). The effect of these new co-therapies on the results of PCI is unknown. METHODS: Clinical outcomes in patients who received co-therapy with ABC, ENOX, or UFH and subsequently underwent an elective (n = 1,064) or urgent (n = 716) PCI in the ASSEN…

MaleAbciximabmedicine.medical_treatmentMyocardial InfarctionAlbertaBelgiumRecurrenceGermanyAbciximabAngioplasty Balloon CoronaryHeart lung and circulation [UMCN 2.1]Netherlandseducation.field_of_studyAntibodies MonoclonalMiddle AgedTreatment OutcomeItalyElective Surgical ProceduresTissue Plasminogen ActivatorDrug Therapy CombinationFemaleCardiology and Cardiovascular MedicineEnoxaparin sodiummedicine.drugmedicine.medical_specialtymedicine.drug_classPopulationLow molecular weight heparinTenecteplasePlatelet Glycoprotein GPIIb-IIIa ComplexDrug Administration ScheduleImmunoglobulin Fab FragmentsFibrinolytic AgentsInternal medicineNorth CarolinamedicineHumansEnoxaparineducationEmergency TreatmentSwedenHeparinbusiness.industryAnticoagulantsPercutaneous coronary interventionSurvival AnalysisSurgerySpainConventional PCITenecteplasebusinessFibrinolytic agentJournal of the American College of Cardiology
researchProduct

Fondaparinux and enoxaparin in comparison to unfractionated heparin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit …

2003

SummaryThe aim of the present study was to investigate the efficacy of three different parenterally administered anticoagulants for the prevention of thrombus formation on artificial heart valves in an experimental rabbit model.Unfractionated heparin was administered intravenously in group I (n = 10), Enoxaparin subcutaneously in group II (n = 10), fondaparinux intravenously in group III (n = 10), and no medication was administered to group IV (n = 9). Leaflets from Sulzer Carbomedics bileaflet mechanical heart valves were placed in a flow chamber. The flow chamber was filled with blood in a continuous circulation between the carotid artery and the jugular vein.In group IV the flow chamber …

MaleArtificial heart valvemedicine.drug_classmedicine.disease_causeFondaparinuxPolysaccharidesmedicineAnimalsHeart valveEnoxaparinThrombusHeparinbusiness.industryAnticoagulantAnticoagulantsThrombosisHematologyHeparinmedicine.diseaseFondaparinux SodiumMicroscopy Electronmedicine.anatomical_structureFondaparinuxHeart Valve ProsthesisAnesthesiaBlood Coagulation TestsRabbitsbusinessEnoxaparin sodiummedicine.drugThrombosis and Haemostasis
researchProduct

Regional anticoagulation with heparin of an extracorporeal CO2 removal circuit: a case report

2019

Abstract Background Extracorporeal carbon dioxide removal is an increasingly used respiratory support technique. As is true of all extracorporeal techniques, extracorporeal carbon dioxide removal needs proper anticoagulation. We report a case of a patient at risk of bleeding complications who was treated with extracorporeal carbon dioxide removal and anticoagulated with a regional technique. Case presentation A 56-year-old Caucasian man with a history of chronic obstructive pulmonary disease exacerbation required extracorporeal carbon dioxide removal for severe hypercapnia and acidosis despite mechanical ventilation. The extracorporeal circuit was anticoagulated using a regional heparin tec…

MaleExtracorporeal CirculationLow platelet countExacerbationmedicine.medical_treatment2lcsh:MedicineCase Report030204 cardiovascular system & hematologyExtracorporealExtracorporeal carbon dioxide removal03 medical and health sciencesContinuous venovenous filtrationPulmonary Disease Chronic Obstructive0302 clinical medicineExtracorporeal CO 2 removalExtracorporeal Membrane OxygenationmedicineHeparin regional anticoagulationHumansAcidosisMechanical ventilationbusiness.industryHeparinMedicine (all)removallcsh:RAnticoagulantsExtracorporeal COGeneral MedicineHeparinExtracorporeal CO2 removalCarbon DioxideMiddle AgedRespiration ArtificialTreatment Outcome030220 oncology & carcinogenesisAnesthesiaDisease Progressionmedicine.symptomContinuous venovenous filtration; Extracorporeal CO ; 2; removal ; Heparin regional anticoagulationbusinessHypercapniamedicine.drugJournal of Medical Case Reports
researchProduct

Evaluation of an automated chromogenic substrate assay for the rapid determination of hirudin in plasma.

1995

Abstract A fully mechanized chromogenic substrate assay method for the rapid and specific determination of recombinant hirudin (r-hirudin) in citrated plasma on clinical chemistry analyzers (Hitachi 911 and Cobas Mira) is described. In a first step, 12 μl sample volume is mixed with the chromogenic substrate. Due to the almost immediate action of hirudin the inhibitory reaction and the cleavage of the substrate is started simultaneously when bovine thrombin is added in excess. This excludes interferences by antithrombin III or heparin cofactor II. The change in absorbance/min is recorded at 405 nm. The measuring range is about 0.2 – 4.0 mg/l r-hirudin on both analyzers. Precision is charact…

MaleHirudinEnzyme-Linked Immunosorbent AssayAbsorbanceAutomationReference ValuesBlood plasmamedicineAnimalsHumansHeparin cofactor IIChromatographyChemistryChromogenicAntithrombinThrombinSubstrate (chemistry)Chromogenic substrate assayHematologyHirudinsMiddle AgedRecombinant ProteinsChromogenic CompoundsCalibrationCattleColorimetryFemalePartial Thromboplastin TimeOligopeptidesmedicine.drugThrombosis research
researchProduct